Assays Meet Interference


By John S. MacNeil


For cell-based assay technology, screening potential drug compounds for activity in disease-related cell lines has traditionally served as its raison d’etre. Like many technologies with applications in drug discovery and development, the advent of automated and multiplexed cell biology assays in the early to mid-’90s was met with optimistic pronouncements of how cell-based assay systems would kick-start the commercialization of new drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.